Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
GASTROINTESTINAL STROMAL TUMOR PIPELINE ANALYSIS
• Gastrointestinal stromal tumors (GISTs) have been endorsed as a biologically peculiar but superior tumor type, different from neural tumors and smooth muscle of the digestive tract (GIT).
• They rule a significant part of gastrointestinal mesenchymal tumors of the GIT and are known to be refractory to conventional chemotherapy or radiation.
• They are both defined and interpreted by the expression of a proto-oncogene protein detected by immunohistochemistry, which serves as a vital diagnostic and therapeutic target.
• Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms in the digestive tract, which, over the last ten years, have emerged from a poorly understood neoplasm to a distinct tumor entity exhibiting molecular abnormalities and for which promising novel treatment modalities have been developed.
• The story of GIST is unique in that targeted molecular therapy was successfully applied in clinical therapeutics, with dramatic results redefining the management of these traditionally chemotherapy-resistant tumors.
• Among the pipeline drugs in mid- to late stage development for GIST most of them are administered via the oral route. Sutent’s (sunitinib) US patents are set to expire in December 2020, which will open the door to generic entry. The distribution of clinical trials across Phases I-IV indicates that majority of tests for GIST have been in early and mid phases of development, with 82.7% of trials in Phase I-II and only 17.3% in Phase III.
• The US has a considerable lead in the number of GIST clinical trials globally. Completed tests dominate the clinical trial activity in the GIS space.
• Novartis leads industry sponsors with the highest number of clinical trials for GIST. Bayer’s regorafenib (StivargaTM) is in the market with fluctuating sales in recent years. Avapritinib of Blueprint Medicines is in late-stage of development. Amcasertib of Boston Medical is in the Phase 2 stage of development while Intuvax of Immunicum is in Phase 1/2 clinical trial.
• From last few years, many institutes and companies have teamed up for developing therapeutics treating gastrointestinal stromal tumor (GIST).
• There are seven emerging firms in the gastrointestinal stromal tumor (GIST), which are eager in seeking an alliance for development opportunities for the maximization of their technology as well as the business platform.
• Among companies dealing with gastrointestinal stromal tumor (GIST) technology, Juno Therapeutics has maidened in the field of collaborations with five collaborations with other companies and three partnerships with universities for the products and technology in recent years. Novartis is the leading company with the positive results of their Gastrointestinal Stromal Tumor (GIST) therapy is pushed ahead with the new clinical trials.
• Gastrointestinal stromal tumors (GISTs) have been endorsed as a biologically peculiar but superior tumor type, different from neural tumors and smooth muscle of the digestive tract (GIT).
• They rule a significant part of gastrointestinal mesenchymal tumors of the GIT and are known to be refractory to conventional chemotherapy or radiation.
• They are both defined and interpreted by the expression of a proto-oncogene protein detected by immunohistochemistry, which serves as a vital diagnostic and therapeutic target.
• Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms in the digestive tract, which, over the last ten years, have emerged from a poorly understood neoplasm to a distinct tumor entity exhibiting molecular abnormalities and for which promising novel treatment modalities have been developed.
• The story of GIST is unique in that targeted molecular therapy was successfully applied in clinical therapeutics, with dramatic results redefining the management of these traditionally chemotherapy-resistant tumors.
• Among the pipeline drugs in mid- to late stage development for GIST most of them are administered via the oral route. Sutent’s (sunitinib) US patents are set to expire in December 2020, which will open the door to generic entry. The distribution of clinical trials across Phases I-IV indicates that majority of tests for GIST have been in early and mid phases of development, with 82.7% of trials in Phase I-II and only 17.3% in Phase III.
• The US has a considerable lead in the number of GIST clinical trials globally. Completed tests dominate the clinical trial activity in the GIS space.
• Novartis leads industry sponsors with the highest number of clinical trials for GIST. Bayer’s regorafenib (StivargaTM) is in the market with fluctuating sales in recent years. Avapritinib of Blueprint Medicines is in late-stage of development. Amcasertib of Boston Medical is in the Phase 2 stage of development while Intuvax of Immunicum is in Phase 1/2 clinical trial.
• From last few years, many institutes and companies have teamed up for developing therapeutics treating gastrointestinal stromal tumor (GIST).
• There are seven emerging firms in the gastrointestinal stromal tumor (GIST), which are eager in seeking an alliance for development opportunities for the maximization of their technology as well as the business platform.
• Among companies dealing with gastrointestinal stromal tumor (GIST) technology, Juno Therapeutics has maidened in the field of collaborations with five collaborations with other companies and three partnerships with universities for the products and technology in recent years. Novartis is the leading company with the positive results of their Gastrointestinal Stromal Tumor (GIST) therapy is pushed ahead with the new clinical trials.
